The CYP2C9*3 variant allele frequency was also a little higher in drug-responsive patients compared with drug-resistant patients (P = 0.06, OR = 0.60, 95% CI = 0.35–1.03), and seems to be contributing toward a lower risk for developing multiple drug resistance in epilepsy [Table 4]. The gene discussed is CYP2C9; the disease is epilepsy.